Key result
Review highlights hypertension and obesity as top AF risk factors and supports NOAC preference.
Why the study?
Atrial fibrillation is a global epidemic with high risk of adverse events, and current evidence on risk factors, complications, and treatment strategies requires summarization.
This review summarizes current evidence on AF management, highlighting the preference for NOACs for stroke prevention and the importance of rate and rhythm control for symptom management.
Emphasizes hypertension and obesity as key modifiable AF risks; leaves open optimal prevention strategies pending prospective trials.
Atrial fibrillation (AF) has become a global epidemic and puts affected patients at high risk of adverse events. In this review we summarise the current evidence on risk factors and complications of AF, describe current treatment strategies, and outline new fields of research. Current evidence shows that hypertension and obesity are the two most important modifiable risk factors for the development of AF. Patients with AF face an increased stroke risk. Oral anticoagulation reduces this risk substantially. Mainly for reasons of safety and ease of use, non-vitamin K antagonist oral anticoagulants are preferred for stroke prevention. Rate and rhythm control interventions remain important and are mainly used for symptom control in AF patients. Rate control is recommended as an initial treatment and in patients with a low or absent symptom burden. Following the advent of AF ablation 20 years ago, the chances of successful sustained rhythm control have increased. Nevertheless, the procedural risks, although low, must be discussed with the patient in the context of the potential benefits. Heart failure and AF often coexist, which creates a further challenge for optimal AF management. Recent studies have shown that AF patients have a high burden of silent brain lesions, and that these lesions are associated with cognitive dysfunction. A better understanding of these interrelationships may eventually help the development of new prevention and treatment strategies to decrease the burden and complications associated with AF.
No takes yet. Share an insight, caveat, or question.
Meyre et al. (2020) conducted a review in Atrial fibrillation. This review summarizes current evidence on atrial fibrillation, highlighting hypertension and obesity as key risk factors and the preference for non-vitamin K antagonist oral anticoagulants.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: